The NANT immunotherapy companies are focused on harnessing the power of the innate immune system to treat cancer and virally induced infectious diseases. NANT''s broad portfolio of biological molecules addresses both the innate (natural killer cell) and the adaptive immune systems (CD8+ T Cells), eliminating the need for high-dose chemotherapy. By leveraging an integrated platform, together with a pipeline of multiple, clinical-stage, immunology programs, NANT''s goal is to create a new standard of care for a wide range of cancers and infectious diseases.